A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: A randomized, controlled trial

Diabetes Care

Volumn 34, Issue 3, 2011, Pages 669-674

  Heise, Tim ^a   Tack, Cees J ^b   Cuddihy, Robert ^c   Davidson, Jaime ^d   Gouet, Didier ^e   Liebl, Andreas ^f   Romero, Enrique ^g   Mersebach, Henriette ^h   Dykiel, Patrik ^h   Jorde, Rolf ⁱ  

^a Profil Institut fur Stoffwechselforschung   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INTERNATIONAL DIABETES CENTER   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e SAINT LOUIS HOSPITAL   (France)

^f Center for Diabetes and Metabolism   (Germany)

^g UNIVERSITY OF VALLADOLID   (Spain)

^h NOVO NORDISK A S   (Denmark)

ⁱ UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC PLUS INSULIN ASPART; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; EVENING DOSAGE; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956136690     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1905     Document Type: Article

References (22)

1. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007;9:648-659
2. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006;23:879-886 (Pubitemid 44141077)
3. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008;31:102-104
4. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-86
5. Kilpatrick ES, Das AK, Orskov C, Berntorp K. Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes. Curr Med Res Opin 2008;24:2651-2661
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
9. Jonassen I, Havelund S, Ribel U, et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multihexamer formation (Abstract). Diabetes 2010;59(Suppl. 1):A11
10. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, a new generation ultralong acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine (Abstract). Diabetes 2010;59(Suppl. 1):A11
11. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions (Abstract). Diabetologia 2010;53(Suppl. 1):S387
12. Jonassen I, Hoeg-Jensen T, Havelund S, Ribel U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation (Abstract). J Pept Sci 2010;16:32
13. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730 (Pubitemid 350005153)
14. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects: 59th WMA General Assembly, Seoul 2008 [article online], 2008. Available fromhttp://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 23 July 2008
15. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1), Step 4 [article online], 1996. Available from http://www.ich.org/LOB/media/MEDIA482.pdf. Accessed 23 July 2008
16. Lindholm A, Jensen LB,Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25:876-882 (Pubitemid 41094286)
17. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16 (Pubitemid 38900899)
18. Wolffenbuttel BH, Klaff LJ, Bhushan R, Fahrbach JL, Jiang H, Martin S. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. Diabet Med 2009;26:1147-1155
19. Strojek K, Bebakar WM, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009;25:2887-2894
20. Horton ES. Defining the role of basal and prandial insulin for optimal glycemic control. J Am Coll Cardiol 2009;53(Suppl.):S21-S27
21. Holman RR, Farmer AJ, Davies MJ, et al.; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. NEngl JMed 2009;361:1736-1747
22. Heise T, Heinemann L. Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Des 2001;7:1303-1325